6 Approved Drugs for IgA Nephropathy and What Their Labels Actually Promise

Your nephrologist says a drug name. You write it on the back of a receipt in the parking lot and look it up that night. The results say the FDA approved it for IgA nephropathy, which feels like the end of the question. It is closer to the beginning, because 6 drugs now carry that approval and they do not all promise the same thing.

Five years ago there were none at all, with not a single therapy approved to treat IgA nephropathy itself. Patients got blood pressure control, a RAS inhibitor, diet advice, and a waiting game, while the most common disease of the kidney's tiny filters anywhere in the world took its course. The absence of treatment was never for lack of interest.

Why IgA Nephropathy Went From 0 Approved Drugs to 6 in 5 Years

The obstacle was arithmetic. To prove a kidney drug works, you have to show it keeps kidneys working, and kidneys fail slowly. A trial built to catch that endpoint runs 10 years or longer and needs thousands of participants with a disease that is not common. Few companies could afford that study, which is why few ran it.

The way out of that trap runs through a word your nephrologist says at every visit, so it helps to be clear on what it means. Healthy kidneys keep protein in your blood, where it belongs. When the filters are damaged, protein escapes into your urine instead, and the more of it that leaks, the more damage is underway. That leak is called proteinuria, a simple urine test measures it, and kidney doctors have tracked it for decades as a sign of how the disease is behaving.

For a long time, regulators would not accept that number as proof that a drug worked. Lowering the leak looked encouraging, but the FDA wanted evidence that patients actually stayed off dialysis, and finding that out meant waiting a decade to watch what happened to them.

In 2019, researchers pooled the results of many earlier IgA nephropathy trials and asked one pointed question. When a treatment lowers the protein leak, do those patients genuinely do better years later? The relationship held up well enough that the FDA agreed to accept the urine number as stand-in evidence of likely benefit. The formal term for that arrangement is a validated surrogate endpoint, and it is the single most consequential thing that has happened to this disease.

The effect was immediate. A drug company could now run a 9-month study measuring urine protein instead of a 10-year study counting dialysis starts. Investment followed and trials launched across the field.

The first approval arrived 2 years after that, and it came from an unexpected direction. Tarpeyo is budesonide, a corticosteroid that has been prescribed for decades in asthma inhalers and for Crohn's disease. What makes it work here is the packaging. The capsule is built to stay sealed until it reaches the lower part of the small intestine, which is where the immune tissue that produces the faulty antibodies actually sits, so the drug acts on the source rather than flooding the whole body with steroid. The FDA cleared it in December 2021 (FDA, 2021). Filspari followed in February 2023, Fabhalta in August 2024, Vanrafia in April 2025, Voyxact in November 2025, and Trutakna this past July. Two more decisions are due before the end of this year.

Every one of the 6 reached patients through accelerated approval, a pathway that works as a loan rather than a gift. The FDA lets a drug onto the market based on the surrogate, in this case a drop in urine protein, on the condition that the company runs a longer confirmatory trial and comes back with evidence on the outcome that actually matters. Slowing the loss of kidney function.

Three of the 6 have now repaid that loan. Tarpeyo converted to full approval in December 2023 on the strength of the NefIgArd trial, becoming the first therapy cleared to reduce loss of kidney function in IgA nephropathy. Filspari converted in September 2024. Fabhalta converted on July 17th of this year, after 24-month APPLAUSE-IgAN results showed a 48% slower decline in kidney function than placebo, a difference of 3.02 mL/min/1.73 m2 per year (Novartis, 2026).

The other 3 are still carrying the debt, and their labels say so, describing proteinuria reduction rather than protection of kidney function. Whether they protect kidney function over years is being tested right now, in trials that have not finished.

None of this makes the newer 3 bad drugs. Accelerated approval exists because making patients wait a decade for a therapy that probably works carries its own harm, and the early signals here have been strong. Voyxact cut proteinuria by 50% at 9 months against a 2% increase on placebo (Otsuka, 2025). Trutakna produced a 42% reduction compared with placebo at 36 weeks in the ORIGIN 3 trial (Vera Therapeutics, 2026). Otsuka has since reported 2-year kidney function data for Voyxact that looks favorable, which is how a conversion starts.

The point is that you should know which kind of promise is printed on your bottle, because the honest answer to how much this drug will protect my kidneys is different for each group.

The 6 Approved IgA Nephropathy Drugs and How Each One Works

IgA nephropathy damages kidneys through a chain of events. The body makes a malformed version of an antibody called IgA1, the immune system attacks it, the resulting clumps lodge in the kidney's filters, and inflammation and scarring follow. The approved drugs interrupt that chain at 4 different points, which is why 2 of them can look nothing alike and both be correct choices.

Tarpeyo (budesonide, delayed release)

A corticosteroid in a capsule designed to dissolve in the lower small intestine, where immune tissue produces the faulty IgA1 in the first place. Taken by mouth as a 9-month course rather than indefinitely. Full approval since December 2023. Being a targeted-release steroid does not make it free of steroid effects, and a safety review still belongs in the conversation.

Filspari (sparsentan)

A daily pill that blocks 2 receptors at once, endothelin A and angiotensin II, reducing the pressure inside the kidney's filters and the protein that escapes them. This one works on the kidney's response to injury rather than the immune cause. Full approval since September 2024. Carries requirements around liver monitoring and pregnancy.

Fabhalta (iptacopan)

An oral inhibitor of complement factor B, part of the immune cascade that amplifies damage once the IgA1 clumps arrive. Converted to full approval in July 2026 and the only complement inhibitor so far cleared on a kidney function claim in this disease. Because it suppresses part of the immune system, vaccination planning and infection monitoring come with it.

Vanrafia (atrasentan)

A daily pill blocking the endothelin A receptor selectively, a cousin of Filspari's approach without the angiotensin half. Accelerated approval since April 2025. Final ALIGN results in February 2026 favored Vanrafia on kidney function but just missed statistical significance on the main measure, and Novartis plans to file for full approval in 2026. Same cautions that follow the endothelin class, including fluid retention, blood pressure, anemia, and pregnancy.

Voyxact (sibeprenlimab)

The first therapy to block APRIL, a signal that drives the B cells making faulty IgA1. Given by injection. Accelerated approval since November 2025, with 2-year kidney function data now reported and a conversion plausibly ahead. Infection risk and vaccine timing matter here too.

Trutakna (atacicept)

Blocks both APRIL and BAFF, 2 signals feeding the same B cells, and is self-administered weekly. The newest of the 6, approved July 7th of this year on accelerated approval. Same immune-suppression considerations as the other B-cell directed options.

Every one of these has a plain-English profile with side effects and trial results in our Drug Decoder, and the IgA nephropathy page puts the approved options side by side along with the trials still recruiting.

Povetacicept and Ultomiris, the 2 IgA Nephropathy FDA Decisions Coming in Late 2026

The field is not finished. Two applications are in front of the FDA right now, both with Phase 3 data already reported, and both could be approved before the end of December. If they are, IgA nephropathy will have gone from zero treatments to 8 in almost exactly 5 years.

Povetacicept (Vertex), decision due November 30th, 2026

Povetacicept blocks APRIL and BAFF together, the same 2 B-cell signals that Trutakna targets, and is given as an injection under the skin once every 4 weeks alongside your usual care. Vertex is seeking accelerated approval based on a planned checkpoint in the Phase 3 RAINIER trial, which enrolled 605 patients and measured them at week 36. Urine protein in the povetacicept group fell 52.0% from where it started, which worked out to a 49.8% drop compared with placebo. A result that size had less than a 1 in 10,000 chance of being a fluke, and every other measure the trial tracked improved as well (Vertex, 2026).

Two details are worth understanding. Vertex spent a priority review voucher to shorten the FDA review from 10 months to 6, which is why the decision arrives November 30th rather than in spring. RAINIER has also not ended. The trial is still running and still blinded, meaning neither the patients nor their doctors know who is receiving the drug, and it continues toward a final readout at 2 years that measures how fast kidney function actually changed. That is the confirmatory evidence, already underway, which puts povetacicept on the same accelerated approval path the other 6 took.

Ultomiris (ravulizumab), decision expected in the fourth quarter of 2026

Ultomiris is not a new drug, which is the most reassuring thing about it. AstraZeneca's Alexion unit already sells it for 4 other rare conditions, including paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis, so doctors have years of real-world safety experience with it. This application asks to add IgA nephropathy to that list. Ultomiris blocks C5, the final step of the complement cascade. Fabhalta blocks an earlier step in that same system, which makes the 2 drugs cousins rather than twins, and approval would make Ultomiris the first C5 blocker cleared for this disease.

In the Phase 3 I CAN trial, urine protein fell 46.6% from baseline at week 34 against 5.6% on placebo, a placebo-adjusted reduction of 43.4%. The effect showed up by week 10 and held through week 34, and it was consistent across patient subgroups (AstraZeneca, 2026). The FDA granted priority review and AstraZeneca has disclosed a fourth-quarter action date without naming the day, which is common when a company would rather not set a public countdown.

What a PDUFA date is and why one decision has a day and the other has a season

Both of those timelines come from the same machinery. Under the Prescription Drug User Fee Act, drugmakers pay fees to the FDA and the agency commits in return to review applications on a clock. A standard review runs 10 months from the day the FDA accepts the filing. A priority review runs 6. The deadline that falls at the end of that clock is the PDUFA date, also called the target action date.

The word action is doing quiet work there. A PDUFA date is the day the FDA promises to respond, not the day it promises to approve. The response can be an approval, or it can be a complete response letter saying the application is not approvable in its current form, which is often about manufacturing or data presentation rather than whether the drug works. The agency can also act early, and occasionally it runs past the date, usually after extending the review to examine new information.

Here is the part that explains your own confusion if you have ever tried to look one of these up. The FDA does not publish PDUFA dates, so companies disclose them or choose not to. Vertex named November 30th, while AstraZeneca has said only that its Ultomiris decision falls in the fourth quarter. Neither is hiding anything improper, they simply made different investor communication choices, and that is why a tracker like ours shows an exact day for one drug and a 3-month window for another.

Povetacicept's date also reflects something patients rarely hear about. Vertex shortened its review from 10 months to 6 by redeeming a priority review voucher. Vouchers are awarded to companies that get a drug approved for a rare pediatric disease or a neglected tropical disease, they can be sold to anyone, and they trade on the open market for enormous sums. The record sale reached $350 million. A company buying one is buying 4 months of calendar, which for a drug like this is 4 months of patients who start treatment sooner.

Both pages on our rare disease FDA calendar update with the outcome when it arrives, and you can get either decision by email the day it happens. Further back, felzartamab, zigakibart, and sefaxersen are working through Phase 3 of their own.

What to Ask Your Nephrologist Before Starting an IgA Nephropathy Drug

These are the questions that separate a prescription you understand from one you simply take.

Is this drug approved on proteinuria or on kidney function

The single most useful question in this whole field right now. It tells you what the evidence behind your treatment actually established, and it costs your nephrologist 10 seconds to answer.

Why this mechanism for me

There are 4 different pathways represented among the 6 approved drugs. The choice should connect to your biopsy, your proteinuria trend, your kidney function trajectory, and your other conditions, not to whichever drug is newest.

What are we measuring and when

Ask what your proteinuria and eGFR are today, what number would count as a response, and when you will check again. KDIGO points toward getting proteinuria below 0.5 g per day and ideally below 0.3, while acknowledging that is not reachable for everyone with established scarring.

What does this do to my infection risk

Four of the 6 work by damping part of the immune system. Vaccination status, timing, and which vaccines are off limits during treatment are part of starting these drugs, not an afterthought.

What happens if this one does not work

With 6 approved and more coming, a first choice is no longer a last choice. Ask what the next option would be and what would trigger switching.

What will this cost me

Every one of these is a specialty drug with prior authorization attached. Ask which specialty pharmacy dispenses it, whether a manufacturer support program exists, and who at the practice handles the appeal if coverage is denied.

IgA Nephropathy Patient Support and Advocacy Resources

Clinical information answers only part of a diagnosis. The IgA Nephropathy Foundation runs monthly virtual support groups split by situation, one for patients, one for caregivers and care partners, and one for people on dialysis or living with a transplant. For a disease where most people have never met another patient, that is a practical resource rather than a sentimental one.

Questions IgA Nephropathy Patients Are Asking About the New Drugs

There is a version of this story that is pure celebration, and it would be fair. A disease that offered nothing but blood pressure pills in 2020 now has 6 approved therapies and 2 more decisions pending, and we wrote that story in March when the Fabhalta data published.

The less comfortable version is the one worth carrying into an appointment. Half of these drugs are still proving they do the thing patients actually want, which is to keep kidneys working. That is not a scandal, it is how the pathway was built, and it was built that way on purpose so people would not have to wait out a decade of trials. Knowing which half you were handed is not pessimism. It is the difference between taking a drug and understanding it.